ERAS

NASDAQ 已收盘

Erasca

14.22 USD
▲+0.46+3.34%
盘后 14.29 +0.49%
2026-11-19
市值
$4.93B
市盈率
—
EPS
-0.99
股息率
—
52 周区间
2.75 – 24.28
成交量
4.78M
Beta
0.65
目标价
25.10
52W 低 2.7552W 高 24.28
价格走势

公司简介

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre...